Molecular and clinical characterization of PARP9 in gliomas: A potential immunotherapeutic target
Molecular and clinical characterization of PARP9 in gliomas: A potential immunotherapeutic target
复制标题
胶质瘤中 PARP9 的分子和临床特征：潜在的免疫治疗靶点
DOI：
10.1111/cns.13380
复制
发表时间：
2020-04
影响因子：
5.5
通讯作者：
Nanxiang Xiong
中科院分区：
文献类型：
--
作者：
Hao Xu;Songshan Chai;Yihao Wang;Jiajing Wang;Dongdong Xiao;Junjun Li;Nanxiang Xiong
Abstract.Background: Glioma is a primary malignancy of the central nervous system (CNS).As biomedicine advances, an efficient molecular target is urgently needed for the diagnosis and treatment of glioma. Meanwhile, several studies have demonstrated that glioma development is closely related to immunity. PARP9 is an inactive monoADP-ribosyltransferase belonging to the poly-ADP ribosyltransferase (ARTD) family. In this article, we aimed to reveal the relationship between PARP9 and glioma and explore the potential prognostic value and immunotherapeutic targetability of PARP9 in glioma. Methods: PARP9 transcript levels were analyzed with TCGA and GEO databases. The clinicopathological information of patients with glioma in the TCGA database and gene expression profiles were analyzed to determine the relationship between the expression of PARP9 and clinicopathologic characteristics. Kaplan-Meier survival analysis, univariate Cox regression analysis, and multivariate Cox regression analysis were used for survival analysis. Gene set enrichment analysis (GSEA) and gene set variation analysis (GSVA) were used for bioinformatics analysis. Correlation analysis explored the relationships between PARP9, infiltrating inflammatory immune cells, and immune checkpoint molecules. Results: PARP9 is highly expressed in glioma, and high expression of PARP9 is associated with poor prognosis and advanced clinicopathological features. Bioinformatics analysis showed that some immune-related pathways were closely associated with high expression of PARP9. Correlation analysis indicated that PARP9 was closely related to inflammatory and immune responses, high immune cell infiltration, and immune checkpoint molecules. Conclusions: PARP9 may serve as an unfavorable prognosis predictor for glioma and a potential immunotherapeutic target.
登录
查看更多内容
DOI：
10.1073/pnas.1720948115
发表时间：
2018-04-24
影响因子：
11.1
作者：
Peranzoni E;Lemoine J;Vimeux L;Feuillet V;Barrin S;Kantari-Mimoun C;Bercovici N;Guérin M;Biton J;Ouakrim H;Régnier F;Lupo A;Alifano M;Damotte D;Donnadieu E
通讯作者：
Donnadieu E
影响因子：
20.3
作者：
Aguiar, RCT;Yakushijin, Y;Shipp, MA
通讯作者：
Shipp, MA
影响因子：
16.6
作者：
Koyama S;Akbay EA;Li YY;Herter-Sprie GS;Buczkowski KA;Richards WG;Gandhi L;Redig AJ;Rodig SJ;Asahina H;Jones RE;Kulkarni MM;Kuraguchi M;Palakurthi S;Fecci PE;Johnson BE;Janne PA;Engelman JA;Gangadharan SP;Costa DB;Freeman GJ;Bueno R;Hodi FS;Dranoff G;Wong KK;Hammerman PS
通讯作者：
Hammerman PS
DOI：
10.1038/nrc3239
发表时间：
2012-03-22
期刊：
Nature reviews. Cancer
影响因子：
--
作者：
Pardoll DM
通讯作者：
Pardoll DM
针对恶性胶质瘤的免疫检查点
影响因子：
--
作者：
Zhang X;Zhu S;Li T;Liu YJ;Chen W;Chen J
通讯作者：
Chen J